youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
GRAL:NASDAQ
Grail Inc
$133.76
arrow_downward
-6.74%(-9.67) 1D
$133.76
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$148.53
High
$149.00
Low
$132.13
Mkt. cap
5.97B
Avg. vol.
1.24M
Volume
983.30K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$148.53
High
$149.00
Low
$132.13
Mkt. cap
5.97B
Avg. vol.
1.24M
Volume
983.30K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
Seeking Alpha
·
14 minutes ago
Nasdaq And S&P 500 Index Lose Momentum, Pull Down Market
GreenevilleSun.com
·
17 minutes ago
More drops for AI and tech stocks overshadow gains for most of Wall Street
BeInCrypto
·
1 hour ago
Yardeni Says Analysts Still See S&P 500 Earnings Near $500 Per Share by 2028
Bloomberg.com
·
13 minutes ago
Nasdaq Slide Clouds Asian Open, Oil Falls on Iran: Markets Wrap
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com